AhR/IL-22 pathway as new target for the treatment of post-infectious irritable bowel syndrome symptoms

Maëva Meynier; Elodie Baudu; Nathalie Rolhion; Manon Defaye; Marjolène Straube; Valentine Daugey; Morgane Modoux; Ivan Wawrzyniak; Frédéric Delbac; Romain Villéger; Mathieu Méleine; Esther Borras Nogués; Catherine Godfraind; Nicolas Barnich; Denis Ardid; Philippe Poirier; Harry Sokol; Jean‐Marc Chatel; Philippe Langella; Valérie Livrelli; Mathilde Bonnet; Frédéric A. Carvalho

doi:10.1080/19490976.2021.2022997

Abstract

strain. Our findings revealed that AhR/IL-22 signaling pathway is altered in a preclinical PI-IBS model. IL-22 delivering alleviate PI-IBS symptoms as colonic hypersensitivity, cognitive impairments, and anxiety-like behaviors by acting on intestinal mucosa integrity. Thus, therapeutic strategies targeting this pathway could be developed to treat IBS patients suffering from chronic abdominal pain and associated well-being disorders.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Meynier et al. (2022) studied this question.

synapsesocial.com/papers/6a008076e92f4a033c8549cd https://doi.org/10.1080/19490976.2021.2022997

View Full Paper

Ask AI

Bookmark

Share

AhR/IL-22 pathway as new target for the treatment of post-infectious irritable bowel syndrome symptoms

Abstract

Discussion

Cite This Study

AhR/IL-22 pathway as new target for the treatment of post-infectious irritable bowel syndrome symptoms

Abstract

Discussion

Cite This Study

Keep reading

Keep reading